Extended-spectrum β-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia

Journal of Microbiology, Immunology and Infection

Volumn 42, Issue 4, 2009, Pages 303-309

  Lee, Chih I ^a   Lee, Nan Yao ^a   Yan, Jing Jou ^a   Lee, Hsin Chun ^a,b   Ko, Nai Ying ^a,b   Chang, Chia Ming ^a   Wu, Chi Jung ^a   Chen, Po Ling ^a   Wang, Li Rong ^a   Ko, Wen Chien ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Bacteremia; Beta lactamases; Cefpodoxime; Drug resistance; Escherichia coli; Klebsiella pneumoniae; Microbial

Indexed keywords

CEFPODOXIME; EXTENDED SPECTRUM BETA LACTAMASE;

ADULT; ANAMNESIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE SEVERITY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MORTALITY; PHENOTYPE; PROGNOSIS; RETROSPECTIVE STUDY; SOLID TUMOR; TAIWAN; UREMIA;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CEFTIZOXIME; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHENOTYPE; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 74849129308     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother. 2004;48:4574-81.
2. Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol. 2007;28:713-9.
3. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007;51:1987-94.
4. Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F, et al. Bloodstream infections caused by extended-spectrum-β-lactamase- producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother. 2006;50:498-504.
5. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for Gram-negative bacteraemia: a commentary. Int J Antimicrob Agents. 1999;11:7-12.
6. Performance standards for antimicrobial susceptibility testing. Eighteenth information supplement. CLSI document, M100-S18. Wayne: Clinical and Laboratory Standards Institute; 2008.
7. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis. 1987;9:1065-78.
8. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(Suppl 2):S82-9.
9. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003;36:1433-7.
10. Marra AR, Wey SB, Castelo A, Gales AC, Cal RG, Filho JR, et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum β-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect Dis. 2006;6:24.
11. Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Risk factors for and outcomes of healthcare-associated infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae in Thailand. Infect Control Hosp Epidemiol. 2007;28:873-6.
12. Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, Cueto M, Gálvez J. Risk-factors for emerging bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Clin Microbiol Infect. 2008;14:180-3.
13. Arpin C, Dubois V, Coulange L, André C, Fischer I, Noury P, et al. Extended-spectrum β-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother. 2003;47:3506-14.
14. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60:913-20.
15. Anderson DJ, Engemann JJ, Harrell LJ, Carmeli Y, Reller LB, Kaye KS. Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2006;50:1715-20.
16. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: variability by site of infection. Arch Intern Med. 2005;165:1375-80.
17. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003;115:529-35.
18. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262-8.
19. Yang K, Guglielmo BJ. Diagnosis and treatment of extended-spectrum and AmpC β-lactamase-producing organisms. Ann Pharmacother. 2007;41:1427-35.
20. Sekowska A, Janicka G, Klyszejko C, Wojda M, Wroblewski M, Szymankiewicz M. Resistance of Klebsiella pneumoniae strains producing and not producing ESBL (extended-spectrum β-lactamase) type enzymes to selected non-beta-lactam antibiotics. Med Sci Monit. 2002;8:BR100-4.
21. Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G. Occurrence of extended-spectrum β-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to β-lactams and other anti-microbial drugs. Antimicrob Agents Chemother. 2002;46:196-202.
22. Sorlózano A, Gutiérrez J, de Dios Luna J, Oteo J, Liébana J, Soto MJ, et al. High presence of extended-spectrum β-lactamases and resistance to quinolones in clinical isolates of Escherichia coli. Microbial Res. 2007;162:347-54.